OncoMatch/Clinical Trials/NCT05039281
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Is NCT05039281 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Atezolizumab and Cabozantinib for recurrent glioblastoma.
Treatment: Atezolizumab · Cabozantinib — This phase I/II trial tests the safety and side effects of atezolizumab in combination with cabozantinib and whether they work to shrink tumors in patients with glioblastoma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab and cabozantinib may help control the disease in patients with recurrent glioblastoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage IV (World Health Organization)
Grade: IV (World Health Organization)
World Health Organization grade IV glioma (glioblastoma or gliosarcoma)
Prior therapy
Must have received: radiation therapy
Patients must have been previously treated with radiation and temozolomide
Must have received: alkylating agent (temozolomide)
Patients must have been previously treated with radiation and temozolomide
Cannot have received: interstitial brachytherapy
Has received prior interstitial brachytherapy
Cannot have received: implanted chemotherapy (Gliadel)
implanted chemotherapy, or therapeutics delivered by local injection or convection enhanced delivery. Prior treatment with Gliadel wafers will be excluded.
Cannot have received: local injection or convection enhanced delivery
therapeutics delivered by local injection or convection enhanced delivery
Cannot have received: Optune device
Active treatment with the Optune device will be excluded
Cannot have received: anti-PD-1 therapy
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Cannot have received: anti-PD-L1 therapy
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Cannot have received: cytotoxic chemotherapy
Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment
Cannot have received: biologic therapy
Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment
Cannot have received: systemic anticancer therapy
Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment
Cannot have received: small molecule kinase inhibitor
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment
Cannot have received: anti-angiogenic therapy
Prior treatment with anti-angiogenic (e.g. anti-vascular endothelial growth factor [VEGF]) therapeutic antibody or pathway targeting agents
Cannot have received: systemic immunostimulatory agent (interferon, interleukin-2)
Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]- or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to cycle 1, day 1
Cannot have received: systemic immunosuppressive medication (prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, anti-TNF agents)
Exception: acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled; inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1
Cannot have received: allogeneic bone marrow transplantation
Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
Cannot have received: solid organ transplantation
Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
Lab requirements
Blood counts
ANC >= 1,500 /mcL; Platelets >= 100,000 /mcL; Hemoglobin >= 9 g/dL or >= 5.6 mmol/L; INR or PT or aPTT <= 1.3 X ULN
Kidney function
Serum creatinine <= 1.5 X ULN OR measured or calculated creatinine clearance >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN; Urine protein/creatinine ratio (UPCR) <= 1 mg/mg OR 24 hour urine protein <= 1g
Liver function
Serum total bilirubin <= 1.5 X ULN OR direct bilirubin <= ULN for subjects with total bilirubin levels > 1.5 ULN; AST and ALT <= 2.5 X ULN; Serum albumin >= 2.8 g/dl
Cardiac function
QTcF <= 500 ms per ECG within 14 days before first dose of study treatment
ANC >= 1,500 /mcL; Platelets >= 100,000 /mcL; Hemoglobin >= 9 g/dL or >= 5.6 mmol/L; Serum creatinine <= 1.5 X ULN OR measured or calculated creatinine clearance >= 60 mL/min; Urine protein/creatinine ratio (UPCR) <= 1 mg/mg OR 24 hour urine protein <= 1g; Serum total bilirubin <= 1.5 X ULN OR direct bilirubin <= ULN; AST and ALT <= 2.5 X ULN; Serum albumin >= 2.8 g/dl; INR or PT or aPTT <= 1.3 X ULN; QTcF <= 500 ms per ECG
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify